These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
999 related articles for article (PubMed ID: 32501454)
21. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial. Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638 [TBL] [Abstract][Full Text] [Related]
22. Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study. Coloretti I; Busani S; Biagioni E; Venturelli S; Munari E; Sita M; DallAra L; Tosi M; Clini E; Tonelli R; Fantini R; Mussini C; Meschiari M; Guaraldi G; Cossarizza A; Alfano G; Girardis M Multidiscip Respir Med; 2021 Jan; 16(1):737. PubMed ID: 34040779 [TBL] [Abstract][Full Text] [Related]
23. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial. Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183 [TBL] [Abstract][Full Text] [Related]
24. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial. Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662 [TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study. Estenssoro E; Loudet CI; Ríos FG; Kanoore Edul VS; Plotnikow G; Andrian M; Romero I; Piezny D; Bezzi M; Mandich V; Groer C; Torres S; Orlandi C; Rubatto Birri PN; Valenti MF; Cunto E; Sáenz MG; Tiribelli N; Aphalo V; Reina R; Dubin A; Lancet Respir Med; 2021 Sep; 9(9):989-998. PubMed ID: 34224674 [TBL] [Abstract][Full Text] [Related]
26. Best evidence in critical care medicine: The role of neuromuscular blocking drugs in early severe acute respiratory distress syndrome. Needham CJ; Brindley PG Can J Anaesth; 2012 Jan; 59(1):105-8. PubMed ID: 22042702 [TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes of intravenous immunoglobulin therapy in COVID-19 related acute respiratory distress syndrome: a retrospective cohort study. Ali HS; Elshafei MS; Saad MO; Mitwally HA; Al Wraidat M; Aroos A; Shaikh N; Ananthegowda DC; Abdelaty MA; George S; Nashwan AJ; Mohamed AS; Khatib MY BMC Pulm Med; 2021 Nov; 21(1):354. PubMed ID: 34743710 [TBL] [Abstract][Full Text] [Related]
28. Longitudinal respiratory subphenotypes in patients with COVID-19-related acute respiratory distress syndrome: results from three observational cohorts. Bos LDJ; Sjoding M; Sinha P; Bhavani SV; Lyons PG; Bewley AF; Botta M; Tsonas AM; Serpa Neto A; Schultz MJ; Dickson RP; Paulus F; Lancet Respir Med; 2021 Dec; 9(12):1377-1386. PubMed ID: 34653374 [TBL] [Abstract][Full Text] [Related]
29. Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial. Bosteels C; Maes B; Van Damme K; De Leeuw E; Declercq J; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B Trials; 2020 Jun; 21(1):491. PubMed ID: 32503663 [TBL] [Abstract][Full Text] [Related]
30. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial. Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A; Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496 [TBL] [Abstract][Full Text] [Related]
31. An open label trial of anakinra to prevent respiratory failure in COVID-19. Kyriazopoulou E; Panagopoulos P; Metallidis S; Dalekos GN; Poulakou G; Gatselis N; Karakike E; Saridaki M; Loli G; Stefos A; Prasianaki D; Georgiadou S; Tsachouridou O; Petrakis V; Tsiakos K; Kosmidou M; Lygoura V; Dareioti M; Milionis H; Papanikolaou IC; Akinosoglou K; Myrodia DM; Gravvani A; Stamou A; Gkavogianni T; Katrini K; Marantos T; Trontzas IP; Syrigos K; Chatzis L; Chatzis S; Vechlidis N; Avgoustou C; Chalvatzis S; Kyprianou M; van der Meer JW; Eugen-Olsen J; Netea MG; Giamarellos-Bourboulis EJ Elife; 2021 Mar; 10():. PubMed ID: 33682678 [TBL] [Abstract][Full Text] [Related]
32. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial. Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ Trials; 2021 May; 22(1):342. PubMed ID: 34001174 [TBL] [Abstract][Full Text] [Related]
33. Patients diagnosed with COVID-19 and treated with anakinra: a real-world study in the USA. Rich C; Eriksson D; Dolfi F; Jablonska K; Dabbous F; Nazir J Clin Exp Immunol; 2022 Apr; 207(2):218-226. PubMed ID: 35020840 [TBL] [Abstract][Full Text] [Related]
34. Intensive care for seriously ill patients affected by novel coronavirus sars - CoV - 2: Experience of the Crema Hospital, Italy. Zuccon W; Comassi P; Adriani L; Bergamaschini G; Bertin E; Borromeo R; Corti S; De Petri F; Dolci F; Galmozzi A; Gigliotti A; Gualdoni L; Guerra C; Khosthiova A; Leati G; Lupi G; Moscato P; Perotti V; Piantelli M; Ruini A; Sportelli S; Susca M; Troiano C; Benelli G; Buscarini E; Canetta C; Merli G; Scartabellati A; Melilli B S C G; Sfogliarini R; Pellegatta G; Viganò G Am J Emerg Med; 2021 Jul; 45():156-161. PubMed ID: 33046317 [TBL] [Abstract][Full Text] [Related]
35. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial. Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765 [TBL] [Abstract][Full Text] [Related]
36. IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study. Franzetti M; Forastieri A; Borsa N; Pandolfo A; Molteni C; Borghesi L; Pontiggia S; Evasi G; Guiotto L; Erba M; Pozzetti U; Ronchetti A; Valsecchi L; Castaldo G; Longoni E; Colombo D; Soncini M; Crespi S; Maggiolini S; Guzzon D; Piconi S J Immunol; 2021 Apr; 206(7):1569-1575. PubMed ID: 33547169 [TBL] [Abstract][Full Text] [Related]
37. Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study. Kooistra EJ; Waalders NJB; Grondman I; Janssen NAF; de Nooijer AH; Netea MG; van de Veerdonk FL; Ewalds E; van der Hoeven JG; Kox M; Pickkers P; Crit Care; 2020 Dec; 24(1):688. PubMed ID: 33302991 [TBL] [Abstract][Full Text] [Related]